A phase III trial of chidamide (HBI-8000; Tucidinostat) in patients with hormone receptor-positive, HER-2 negative late stage breast cancer

Trial Profile

A phase III trial of chidamide (HBI-8000; Tucidinostat) in patients with hormone receptor-positive, HER-2 negative late stage breast cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Tucidinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 New trial record
    • 19 Apr 2017 According to a company media release, GNTbm will be using the same clinical trial protocol (see CT profile 258143) as used by Chipscreen Biosciences for this trial.
    • 19 Apr 2017 According to a GNT Biotech and Medicals Corporation media release, this trial will begin to recruit patients in three months and be completed sometime in 2019, with Chidamide expected to gain its approval for its second indication in 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top